key: cord-0693088-hxq6zazs
authors: Zhu, Jie; Deng, Yong-Qiang; Wang, Xin; Li, Xiao-Feng; Zhang, Na-Na; Liu, Zurui; Zhang, Bowen; Qin, Cheng-Feng; Xie, Zhengwei
title: An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon
date: 2020-05-02
journal: bioRxiv
DOI: 10.1101/2020.05.02.074021
sha: 120d8445f90ba5e9aa998a2dd1665a41cd330624
doc_id: 693088
cord_uid: hxq6zazs

The pandemic COVID-19 has spread to all over the world and greatly threatens safety and health of people. COVID-19 is highly infectious and with high mortality rate. As no effective antiviral treatment is currently available, new drugs are urgently needed. We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs. We found liquiritin significantly inhibit replication of SARS-CoV-2 in Vero E6 cells with EC50 = 2.39 μM. Mechanistically, we found liquiritin exerts anti-viral function by mimicking type I interferon. Upregulated genes induced by liquiritin are enriched in GO categories including type I interferon signaling pathway, negative regulation of viral genome replication and etc. In toxicity experiment, no death was observed when treated at dose of 300 mg/kg for a week in ICR mice. All the organ indexes but liver and serum biochemical indexes were normal after treatment. Liquiritin is abundant in licorice tablet (~0.2% by mass), a traditional Chinese medicine. Together, we recommend liquiritin as a competitive candidate for treating COVID-19. We also expect liquiritin to have a broad and potent antiviral function to other viral pathogens, like HBV, HIV and etc.

Began at the end of year 2019, a novel coronavirus named SARS-CoV-2 caused outbreaks of pulmonary diseases (COVID- 19) worldwide. It has greatly threatened the public health in global and killed tens-of-thousands of people 1 . By May 2nd, there are > 340,000 cumulative cases globally, with > 240,000 deaths. At present, some drugs are considered modestly effective in treating COVID-19, including chloroquine and remdesivir. However, the efficacy and safety of these drugs for SARS-CoV-2 pneumonia patients are not conclusive after several clinical trials. Current studies showed controversial effects in different trials 2 . As there is no specific treatment against COVID-19, identifying effective and safe antiviral agents to combat the disease is urgently needed.

Previous strategies for anti-viral drug development mainly focus on blocking receptors or inhibiting proteases. However, boosting the protective ability of the host was rarely considered. Herein, we consider a method to inhibit the gene expression of multiple factors that related to viral replication with one single compound. Previously, the chemical treated cell cultures were measured and analyzed by microarray or L1000 techniques 3, 4 . The gene set enrichment analysis (GSEA) or Venn diagram were applied to connect the gene expression profile to up / down gene sets of certain diseases. Such technique, named connectivity map (CMAP) has been applied in screening drugs for obesity 5, 6 . We proposed that similar strategy can be applied to inhibit host machinery proteins that supporting the viral replication and to induce genes that blocking the viral replication.

Liquiritin is one of the main flavonoids in Glycyrrhiza uralensis, which acts as an antioxidant and has antidepressant, neuroprotective, anti-inflammatory and therapeutic effects on heart system diseases [7] [8] [9] [10] [11] . Liquiritin plays a strong protective effect on vascular endothelial cells in myocardial ischemia-reperfusion injury model 11 . It can also protect smokinginduced lung epithelial cell injury 12 .

Type I interferon (INF) is important cytokines to protect host from viral infection. Almost all human cells can produce INFα/β, which are the best-defined type I INFs. INFs are able to induce the downstream IFN stimulated genes (ISGs) to inhibit the viral replication, including MX1, PKR, OAS, IFITM, APOBEC1, TRIM and etc 13 .

In present study, we first predicted the efficacy of compounds to inhibit the viral replication. Then, we tested them using Vero E6 cell lines. We found liquiritin is able to inhibit infection of SARS-CoV-2 efficiently with EC50 = 2.39 µM. Mechanistically, we found liquiritin mimicked type I INF to induce ISGs and thus protect cells from infection. We also evaluated the bioavailability, metabolism and safety of liquiritin.

To perform GSEA against chemical induced transcriptomes, a gene set is required. In the case of SARS-CoV-2, a reasonable gene set that are enriched in viral processes by analyzing the ACE2-expressed AT2 cells were reported by Zhao et. al 14 . These genes include TRIM27, IFITM3, TMPRSS2, LAMP1 and etc. The full list is shown in Methods section. We chose the FDA approved drugs and natural products as the compound library (3682 in total). We employed InfinityPhenotype 15 , which is an artificial intelligence based platform, to predict efficacy of potential drugs (Figure 1a) . InfinityPhenotype takes molecule formula as input and calculate the enrichment score, similar as in CMAP, but only one side is considered. All the scores were plotted in Figure 1b . The top scored compounds are shown in Supp. Table 1 . In the natural product list, liquiritin (-0.32) and agnuside (-0.31) have emerged. In FDA approved drugs, we obtained procaterol (-0.23), pibrentasvir (-0.23) and carbocisteine (-0.21). Liquiritin ranks first among all the compounds.

To experimentally verify the predicted results, we measured the effects of these compounds on the virus yield and infection rates of SARS-CoV-2. First, a cytopathic effect (CPE) inhibition assay with only one dose was performed in Vero E6 cells (ATCC-1586) for fast screening. Among the five tested drugs, liquiritin exhibited significant CPE inhibition at 10 µM qualitatively. We then employed qRT-PCR to quantify the inhibition and expanded the concentration from 0.1 to 100 µM. Vero E6 cells were infected with SARS-CoV-2 at 100 µl median tissue culture infectious dose (TCID50). Notably, liquiritin potently blocked virus infection at low-micromolar concentration (EC50 = 2.39 µM, Figure 1c ). Liquiritin ranks first. c) The antiviral activity of liquiritin in Vero E6 cells (EC50 = 2.39 µM, n = 3 for where error bar is shown). d) Cytotoxicity of the liquiritin to Vero E6 cells was measured by MTS assay.

The transcriptomic change induced by liquiritin (Figure 2a ) in MCF7 cells was reported by Li et al 4 . Gene Ontology analysis reveals that the upregulated genes are enriched in the "type I interferon signaling pathway", "negative regulation of viral genome replication", "defense response to virus" and "response to virus" categories ( Figure 2b ) with p-value < 8.26e-4, 8.29e-4, 0.0021 and 0.0039, respectively. Nine genes in the first category were IFIT1, IFIT3, IFITM1, IFI6, IFI27, OAS3, OAS1, PSMB8 and IRF8. The induced ISGs include MX1, OAS, IFIT, IFITM and etc. as shown in the "negative regulation of viral genome replication" category. IFIT1 and IFIT3 belong to the type I interferon (IFN)-induced protein with tetratricopeptide repeats (IFIT) family and IFITM1 belongs to the IFN-induced transmembrane protein (IFITM) family. Thus, liquiritin exhibits a general anti-viral activity by mimicking the type I IFN. Further, the enrichment analysis of protein-protein interaction networks reveals a significant module composed of nine ISGs (Figure 2d ). Other genes in this module indicate potential regulators of these ISGs.

Further, the "inflammatory response" is also enriched in down-regulated genes with pvalue < 0.015 (Figure 2c) , showing liquiritin reduced inflammatory response. In this category, IL13, IL17B and etc. showed up. This may be beneficial for avoiding the cytokine storm observed in COVID-19. and that of downregulated genes (c). d) The most significant module of the protein-protein interaction (PPI) network of upregulated genes. Node size is positively related to degree of genes and the gradation of color positively associated with the expression change of this gene.

Liu et al. 18 found derivatives of flavones efficiently inhibit 3CL pro , which is a conserved protease for SARS-CoV-2 replication. Liquiritin is also a derivative of flavones, specifically it is a monosaccharide derivative and a monohydroxyflavanone. It has a mother nucleus structure similar to the compounds found by Liu et al. Though molecule docking showed there might be a binding to 3CL pro , liquiritin didn't show any inhibitory effects to the activity of 3CL pro in vitro at 12.5, 25.0 and 50.0 µM (data not shown).

To evaluate the safety of liquiritin, the cytotoxicity in Vero E6 cells was determined by MTS assay (CC50 = 29.46 µM, Maximal inhibition of cell growth is 70%, as shown in Figure  1d ). We further examined the toxicity in vivo. No morality was observed at 150 mg/kg dose of one-time treatment of liquiritin by intravenous administration during the 14 days monitoring period (Figure 3a ). Mice intravenous administration 150 mg/kg of liquiritin did not manifest any signs of toxicity during this observation period. The body weight, food intake and water intake are shown in Figure 3b , c. A continuous treatment for seven days at 300 mg/kg was also performed. The mortality rate is also zero (Figure 3d ). The intake food, body weights were all kept at normal level (Figure 3e, f). As reported in literatures, liquiritin has no significantly cytotoxic effects in L-02, GES-1, IMR-90 and 293T cells with different concentrations (30, 60, 90, 120, and 150 µM) and the MTT assay results confirmed that 345 µM liquiritin has no influence on the viability of RA-FLS cells 16, 17 .

For both assays shown in Figure 3a , d, we also measured organ and serum biochemical indexes. No significant differences organ indexes (ratio of organ weight to body weight) were observed except liver index compared with the control mice. Meanwhile, levels of glucose, cholesterol, triglyceride, high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) kept normal after liquiritin administration. We observed declined ALT and it may be due to the anti-inflammatory effect of liquiritin. Meanwhile, no abnormality was observed in levels of blood UREA、UA、CK、α-HBDH, suggesting renal function and heart function were not harmed. Though some relevant index of blood analysis, such as the number of leukocytes, neutrophils and etc., in the control mice and liquiritin-treated mice are different, they are all within the range of reference values, indicating that liquiritin has no obvious toxicity (Supplementary Table 6 administration for seven days in ICR mice.

To evaluate the pharmacokinetics of liquiritin, we searched literatures and found the pharmacokinetic data of mixtures containing liquiritin (Supp. Table 2 ). The corresponding dose of liquiritin is range from 225 to 44, 000 ug/kg, the Cmax in serum is range from 0.064 to 2.3 µM. The Tmax is range from 0. 25 to 0. 6 hours and T1/2 is range from 1.9 to 11.63 hours. As the bioavailability is low and degradation is fast, we suggest an intravenous or inhalation administration for liquirtin.

To find drugs that may cure COVID-19, we adopted a different strategy by analyzing transcriptional changes induced by various compounds. We found that liquiritin is highly effective in the inhibition of SARS-CoV-2 infection in vitro compared to other SARS-CoV-2 drugs reported in vitro (Supp. Table 3 ). Since liquiritin is also one of the main ingredients of compound licorice tablets, we speculate that it is safe. Indeed, it didn't show toxicity and side effects in two independent experiments. In summary, we suggest that liquiritin should be assessed in human patients suffering from the COVID-19.

Mechanistically, we found liquiritin induced the expression of anti-viral genes. GO analysis revealed that "type I INF signaling pathway" was activated. We thus proposed that liquiritin may mimic type I INF to inhibit the viral replication. Vero E6 cell line we used here lack IFNB1 gene and cannot synthesize interferon. However, Vero E6 cells contain the trans-acting factors needed for human beta interferon 20 We also surveyed the literatures for the targets of liquiritin. It's reported that liquiritin, a flavonoid isolated from Glycyrrhiza, is a potent and competitive AKR1C1 inhibitor with IC50 of 0.62 µM, 0.61 µM, and 3.72µM for AKR1C1, AKR1C2 and AKR1C3, respectively 19 . Whether AKR1 is the major target for liquiritin's anti-viral activity is unclear. Further experiments need to be carried out.

So far, there are no first principles to precisely simulate the intrinsic interactions of cells. One alternative solution is to use the measured data to overcome the difficulty of complex systems. Deep neural network offers an option to empirically fit high dimensional data. InfinityPhenotype we employed here is based on transcriptional change induced by compounds. Such framework treated a broad range of interactions inside the cells, from ligand-protein interaction to transcriptional regulations, as well as other hidden interactions, as a black box. It offers us an opportunity to predict the efficacy of compounds in a precise manner.

To test if other gradients in liquorice inhibit the viral replication, we also tested liquiritigenin and glycyrrhizic acid in Vero E6 cells. Neither of them showed inhibitory effect (data not shown). Further animal test, transcriptional measurement with virus in Vero E6 cells and in mice are still ongoing. Because type I interferon is responsive to most viruses that infect vertebrate, we expect liquiritin having a broad and potent antiviral function to other viral pathogens, like HBV, HIV and etc.

The stock of SARS-CoV-2 strain BetaCoV/wuhan/AMMS01/2020 was originally isolated from a patient returning from Wuhan. The virus was amplified and titerated by standard plaque forming assay on Vero cells. All experiments involving infectious SARS-CoV-2 were performed in biosafety level 3 (BSL3) containment laboratory in AMMS. Vero cell were purchased from ATCC (Cat# CCL-81) and cultured in DMEM supplemented with 10% FBS at 37℃.

The full list of genes used for enrichment analysis (GSEA) includes SLC1A5, CXADR, CAV2, NUP98, CTBP2, GSN, HSPA1B, STOM, RAB1B, HACD3, ITGB6, IST1, NUCKS1, TRIM27, APOE, SMARCB1, UBP1, CHMP1A, NUP160, HSPA8, DAG1, STAU1, ICAM1, CHMP5, DEK, VPS37B, EGFR, CCNK, PPIA, IFITM3, PPIB, TMPRSS2, UBC, LAMP1 and CHMP3. Kolmogorov-Smirnov (KS) test is used to evaluate the distribution of query genes in reference list. The gene expression fold change was calculated by InfinityPhenotype platform and used to make the rank list (>10,000 in this case). The ES score for one gene set is defined as:

where t is the number of genes in the targeted gene set, n is the number of genes in full gene expression profile, V(j) is the rank of a specific gene in the rank list.

The cytotoxicity of the tested drugs on Vero Cell were determined by MTS cell proliferation assays (Promega, USA), according to manufacturer's protocol. Briefly, ~1 × 104 cells were seeded into a 96-well plate and incubated for 20-24 h at 37 °C. The media was removed, and 100 µl of media containing decreasing concentrations of antiviral compound were added to the wells. All determinations were performed in triplicate. After 4 days incubation at 37 °C, MTS assays were performed according to manufacturers' protocols. A microtiter plate reader (SYNERGY HTX, BioTek Instruments) with a 490 nm filter was used to record absorbance. After adjusting the absorbance for background and comparing to untreated controls, the cytotoxic concentration CC50 was calculated using a sigmoidal nonlinear regression function to fit the dose-response curve using the GraphPad Prism 7.0 software.

The in vitro antiviral efficacy of the tested drug on Vero E6 Cell was performed as we previously described [Jin, et al., 2020] . Briefly, ~1 × 104 cells were seeded into a 96-well plate and incubated for 20-24 h at 37 °C. Cells were pre-treated with the indicated antivirals (10 µM) for 1 h, and the virus (MOI of 0.01) was subsequently added to allow infection for 2 h. Then, the virus-drug mixture was removed and cells were further cultured with fresh drug-containing medium. At 48 h p.i., viral RNA copy in supernatants were quantified by qRT-PCR assays with the SARS-CoV-2-specific primers.

ICR mice were used to test the in vivo safety of liquiritin. Thirty-Six ICR male and female mice were purchased from the Peking University Animal Department. The animals were housed in a temperature-controlled animal room (24 ± 2 ℃) with a relative humidity of 60-80%. All mice were fasted overnight but given water ad libitum prior to dosage. Animals were divided into two groups with 6 males and 6 females at random. Liquiritin was dissolved in 10% DMSO/40% PEG400/50% Saline and administered i.v. once at doses of 150mg/kg, and administered i.p. once a day for 10 days at doses of 300mg/kg. Their general behavior, signs of toxicity, body weights and mortality were recorded after the administration of liquiritin. Animals were killed by excessive anesthesia. Gross necropsy, weighing, calculation of organ index (brain, heart, lung, liver, kidney, adrenal gland, thymus, spleen, testis, epididymis, ovary, uterus, thyroid), pathological examination of the organs was carried out afterwards. The blood sample was analysis by blood analyzer HEMAVET 950FS.

Microarray data on gene expression (GSE85871) was downloaded from Gene Expression Omnibus (GEO). The DEGs between normal and liquirintin-treated MCF7 cells were also screened by the limma package. |log2FC| ≥ 0.5, adjust p-value < 0.05 were considered statistically significant for the DEGs. To elucidate potential biological process associated with the DEGs, we performed GO enrichment analysis utilizing the Database for Annotation, Visualization and Integrated Discovery (DAVID). p-value < 0.05 was defined as the cut-off criteria. The upregulated DEGs were mapped to STRING to evaluate the PPI information and set confidence score > 0.4 as the cut-off standard. Cytoscape was used to visualize the PPI network, a practical open-source software tool for the visual exploration of biomolecule interaction networks consisting of protein, gene and other types of interaction.

A colorimetric substrate Thr-Ser-Ala-Val-Leu-Gln-pNA (GL Biochemistry Ltd) and assay buffer (40 mM PBS, 100 mM NaCl, 1 mM EDTA, 0.1% Triton 100, pH 7.3) was used for the inhibition assay. Stock solutions of the inhibitor were prepared with 100% DMSO. The 100 µl reaction systems in assay buffer contain 0.5 µM protease and 5% DMSO or inhibitor to the final concentration. First, dilute SARS-CoV-2 3CLpro with assay buffer to the desired concentration. 5 µl DMSO or inhibitor at various concentrations was pre-incubated with 85 µl diluted SARS-CoV-2 3CLpro for 30 min at room temperature. And then add 10 µl 2 mM substrate Thr-Ser-Ala-Val-Leu-Gln-pNA (dissolved in water) into above system to final concentration of 200 µM to initiate the reaction. Increase in absorbance at 390 nm was recorded for 20 min at interval of 30 s with a kinetics mode program using a plate reader (Synergy, Biotek). The percent of inhibition was calculated by Vi/V0, where V0 and Vi represent the mean reaction rate of the enzyme incubated with DMSO or compounds. IC50 was fitted with Hill function. 

A Novel Coronavirus from Patients with Pneumonia in China

Compassionate Use of Remdesivir for Patients with Severe Covid-19

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs

Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice

Licorice inhibits 11 betahydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action

Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells

Phenolic constituents of licorice. VIII. Structures of glicophenone and glicoisoflavanone, and effects of licorice phenolics on methicillin-resistant Staphylococcus aureus

Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development

Neuroprotective effect of liquiritin against focal cerebral ischemia/reperfusion in mice via its antioxidant and antiapoptosis properties

Protective effects of liquiritin apioside on cigarette smoke-induced lung epithelial cell injury

Type I interferons in infectious disease

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov bioRxiv preprint

Liquiritin from Glycyrrhiza uralensis Attenuating Rheumatoid Arthritis via Reducing Inflammation, Suppressing Angiogenesis, and Inhibiting MAPK Signaling Pathway

Liquiritin inhibits proliferation and induces apoptosis in HepG2 hepatocellular carcinoma cells via the ROS-mediated MAPK/AKT/NF-kappaB signaling pathway

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro

Liquiritin, as a Natural Inhibitor of AKR1C1, Could Interfere With the Progesterone Metabolism

Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis

Pharmacokinetic Assessments of Liquiritin, Protocatechuic Aldehyde and Rosmarinic Acid in Rat Plasma by UPLC-MS-MS After Administration of ZibuPiyin Recipe

Pharmacokinetics study of 16 representative components from Baoyuan Decoction in rat plasma by LC-MS/MS with a large-volume direct injection method

Simultaneous quantification of paeoniflorin, nobiletin, tangeretin, liquiritigenin, isoliquiritigenin, liquiritin and formononetin from Si-Ni-San extract in rat plasma and tissues by liquid chromatography-tandem mass spectrometry

Simultaneous quantification of catechin, epicatechin, liquiritin, isoliquiritin, liquiritigenin, isoliquiritigenin, piperine and glycyrrhetinic acid in rat plasma by HPLC-MS/MS: application to a pharmacokinetic study of Longhu Rendan pills

Simultaneous determination of puerarin, daidzin, daidzein, paeoniflorin, albiflorin, liquiritin and liquiritigenin in rat plasma and its application to a pharmacokinetic study of Ge-Gen Decoction by a liquid chromatography-electrospray ionization-tandem mass spectrometry

Data are means ± SEM, control (n=3); liquiritin (n=6); *P< 0.05 compared with control mice. Data are means ± SEM, control (n=3); liquiritin (n=3); liquiritin-recovery (n=3); *P< 0.05 compared with control mice.